GlassScriptPhysician profile
Marc L Bernstein
NPI 1396040366
$199,269.53
in general payments reported to CMS, 2019-2025
47 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,106 · 2021: $3,847 · 2022: $20K · 2023: $16K · 2024: $51K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Travel and Lodging: $33K · Consulting Fee: $11K · Food and Beverage: $9,812 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,750.00 |
| Travel and Lodging | $32,518.35 |
| Consulting Fee | $10,800.00 |
| Food and Beverage | $9,812.25 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $172,504.51 | 2021-2025 | Omvoh |
| Eli Lilly and Company | $14,457.21 | 2022-2025 | Omvoh |
| Abbvie INC. | $4,184.66 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,272.26 | 2019-2025 | Xifaxan, Relistor |
| Janssen Biotech, INC. | $990.31 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $823.24 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $699.04 | 2019-2025 | |
| Celgene Corporation | $615.12 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $412.67 | 2020-2024 | Linzess |
| Genzyme Corporation | $387.01 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $297.85 | 2020-2023 | |
| Ardelyx, INC. | $260.00 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $213.99 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $156.40 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $150.28 | 2024-2025 | Vowst, Zenpep |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $149.50 | 2020-2021 | |
| Smith+Nephew, INC. | $142.16 | 2024 | Q-Fix, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Axonics, INC. | $129.35 | 2023 | Axonics |
| Steris Corporation | $108.36 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $98.30 | 2023 | Fujifilm |
| Braintree Laboratories, INC. | $97.46 | 2019-2025 | Suflave, Sutab |
| Boston Scientific Corporation | $92.39 | 2019-2024 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $87.15 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $87.08 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $79.06 | 2020-2023 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $78.38 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $73.38 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $71.82 | 2024-2025 | Bylvay, Iqirvo |
| Ucb, INC. | $71.22 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $67.31 | 2019-2023 | Rebyota |
| Vivus LLC | $57.63 | 2021-2024 | Pancreaze |
| Palette Life Sciences, INC. | $50.52 | 2022 | |
| Fresenius Kabi USA, LLC | $47.00 | 2023-2024 | Idacio |
| Allergan, INC. | $27.33 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $23.36 | 2023 | Terlivaz |
| Celltrion USA INC. | $22.34 | 2025 | Vegzelma |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Shionogi INC | $20.59 | 2019 | |
| Medtronic, INC. | $20.00 | 2021 | |
| Sandoz INC. | $17.91 | 2025 | Hyrimoz |
| Organon LLC | $17.57 | 2023 | Hadlima |
| Intra-Sana Laboratories | $16.97 | 2022 | |
| Daiichi Sankyo INC. | $16.82 | 2019 | |
| Alfasigma USA, INC. | $15.04 | 2020 | |
| Evoke Pharma, INC. | $14.62 | 2021 | |
| Conmed Corporation | $12.91 | 2019 | |
| Endogastric Solutions, INC | $9.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.